Nuvectis Pharma has secured major clinical and regulatory validation for ciprocopan, also known as NXP100, after China approved the once-daily oral Complement Factor B inhibitor for treatment-naive patients with paroxysmal nocturnal hemoglobinuria. The National Medical Products Administration approval represents ciprocopan’s first marketing authorization globally and follows a head-to-head Phase 3 trial that produced stronger hemoglobin and transfusion-avoidance results than eculizumab. The milestone strengthens the development case for ciprocopan outside Asia, although Nuvectis Pharma must still navigate separate regulatory requirements before it can pursue the larger markets covered by its licensing agreement.
Why China’s approval of ciprocopan matters for treatment-naive patients with paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria, commonly known as PNH, is a rare acquired blood disorder in which red blood cells are destroyed prematurely. The resulting hemolysis can cause anemia, fatigue, weakness and shortness of breath, while patients may also face potentially serious complications involving abnormal blood clotting. Because PNH is a chronic condition, the convenience, durability and safety of treatment can materially influence how patients manage the disease over many years.
Ciprocopan was approved in China for patients who had not previously received a complement inhibitor. According to Nuvectis Pharma, this makes the drug the first globally approved once-daily oral Complement Factor B inhibitor, an important distinction in a treatment category where dosing convenience could become a competitive advantage.
That description must be interpreted carefully. Ciprocopan is not the first oral Factor B inhibitor approved for PNH. The United States Food and Drug Administration approved Novartis’ Fabhalta, or iptacopan, in 2023 as an oral monotherapy for adults with PNH. Fabhalta is administered twice daily, while ciprocopan’s proposed differentiation rests partly on its once-daily dosing schedule.
The competitive argument therefore extends beyond whether oral Factor B inhibition works. The commercial contest will involve dosing frequency, efficacy, safety, regulatory breadth, payer access and physicians’ willingness to move patients away from established complement therapies. Ciprocopan’s Chinese approval gives the molecule a meaningful credential, but it is entering a field that already includes globally established pharmaceutical companies and increasingly diverse complement-targeting approaches.
How ciprocopan’s Phase 3 results against eculizumab support its once-daily Factor B proposition
China’s approval was primarily supported by a head-to-head Phase 3 trial comparing ciprocopan with Soliris, or eculizumab, in treatment-naive PNH patients. The study met its primary and secondary endpoints, according to Nuvectis Pharma, and reported superiority for ciprocopan across several clinically relevant measures.
A hemoglobin target of 12 grams per deciliter was reached by 59.5% of patients receiving ciprocopan, compared with 8.3% of patients treated with eculizumab. The average increase in hemoglobin from baseline was approximately 5.0 grams per deciliter with ciprocopan and 2.2 grams per deciliter with eculizumab.
The transfusion data also favored ciprocopan. Approximately 94.6% of ciprocopan-treated patients did not require transfusions during the study, compared with 69.4% of patients in the eculizumab group. Nuvectis Pharma also reported that no adverse events in the ciprocopan arm led to treatment discontinuation or withdrawal from the study.
These findings are important because hemoglobin improvement and transfusion avoidance directly address major burdens associated with PNH. A treatment that can control red blood cell destruction while reducing transfusion dependence could offer both clinical and quality-of-life benefits, although the complete study design, statistical analysis and longer-term safety experience will remain important when regulators outside China assess the program.
Ciprocopan inhibits Complement Factor B, which plays a central role in amplification of the alternative complement pathway. This upstream mechanism is intended to control both intravascular hemolysis, which occurs inside blood vessels, and extravascular hemolysis, which occurs when damaged red blood cells are cleared elsewhere in the body.
That mechanism differs from terminal complement inhibitors such as eculizumab, which target Complement Component 5. The Phase 3 comparison suggests ciprocopan may provide broader control of hemolysis in the studied population, but a single approval does not establish superiority across every PNH patient group, treatment setting or geographic market.
What the China approval means for Nuvectis Pharma’s ex-China development and commercialization strategy
Ciprocopan was independently developed by Haisco Pharmaceutical Group, which retains responsibility for development, regulatory approvals and commercialization in China. Nuvectis Pharma licensed rights to develop and commercialize the drug outside Greater China, India and certain Southeast Asian countries in June 2026.
This ownership structure creates an important distinction between clinical validation and immediate commercial revenue. The Chinese approval validates the drug candidate and the underlying Phase 3 package, but Chinese ciprocopan sales would primarily fall within Haisco Pharmaceutical Group’s retained territory rather than Nuvectis Pharma’s licensed markets.
Nuvectis Pharma’s opportunity lies in using the Chinese regulatory outcome and clinical data to support development in the United States, Europe and other international territories. The company has not yet disclosed a detailed timetable for a United States submission, a European filing or any additional studies that regulators may require.
Regulators outside China will conduct independent reviews and may seek additional information concerning study conduct, patient demographics, manufacturing, safety monitoring or the applicability of the Chinese data to their populations. Nuvectis Pharma may also need bridging studies or broader multinational clinical evidence, depending on its discussions with regulatory agencies.
A separate Chinese application covering PNH patients previously treated with anti-C5 therapies remains under regulatory review. Approval in that population would broaden ciprocopan’s position beyond newly treated patients and offer further evidence about its potential role in patients switching from established complement inhibitors.
The licensing economics also create substantial future obligations. Nuvectis Pharma agreed to upfront and near-term payments totaling up to $40 million for ciprocopan and the BRAF inhibitor NXP200. Haisco Pharmaceutical Group is eligible for up to approximately $1.421 billion in additional development, regulatory and commercial milestone payments, along with tiered royalties on future net sales.
Those payments reflect the scale of the opportunity but also raise the threshold for commercial success. Nuvectis Pharma will need ciprocopan to generate enough value in its licensed markets to absorb development expenditure, milestone payments, royalties and the cost of building or securing commercial infrastructure.
Why Nuvectis Pharma stock sentiment is positive but still tied to global regulatory execution
Nuvectis Pharma shares were trading at approximately $19.72 at around 10:43 a.m. Eastern Time on July 23, up about 2.2% from the previous close. The stock’s measured reaction suggests investors viewed the approval positively, although the movement was not large enough to indicate that the market had removed the program’s remaining development and commercialization risks.
The shares were also trading about 1.4% below the $20 price of Nuvectis Pharma’s recent public offering. The company priced five million shares at $20 each in late June, targeting $100 million in gross proceeds, with the funding intended to support NXP100, NXP200, NXP900 and general corporate needs.
Investor sentiment appears constructive because the China approval converts ciprocopan from a promising licensed asset into an approved medicine in at least one market. That transition lowers scientific and regulatory uncertainty around the molecule itself.
However, it does not eliminate the risks facing Nuvectis Pharma. The company remains responsible for advancing ciprocopan in its own territories, competing against approved oral and injectable complement therapies, financing international development and eventually establishing a viable commercialization strategy.
The most valuable future catalysts are likely to include regulatory guidance from the United States Food and Drug Administration and European authorities, details of any required global studies, the outcome of the second Chinese PNH application and evidence that ciprocopan can be developed across additional complement-mediated diseases.
Ciprocopan’s approval is a genuine value-creating milestone because it validates a once-daily oral Factor B inhibitor in a head-to-head Phase 3 trial against an established PNH therapy. The hemoglobin and transfusion-avoidance results provide Nuvectis Pharma with a stronger foundation for discussions with regulators and potential commercial partners outside Asia.
The approval does not yet establish a direct Chinese revenue stream for Nuvectis Pharma, nor does it guarantee approval in the United States or Europe. The next phase of the story will depend on whether the company can translate Haisco Pharmaceutical Group’s Chinese success into an efficient global development program and a commercially differentiated position against Novartis and other complement-therapy competitors.
